Ascendis Total Assets from 2010 to 2024
| ASND Stock | USD 129.90 3.24 2.56% |
Total Assets | First Reported 2013-12-31 | Previous Quarter 758.7 M | Current Value 758.3 M | Quarterly Volatility 416.8 M |
Check Ascendis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascendis Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.4 M, Interest Expense of 46.3 M or Selling General Administrative of 277.6 M, as well as many indicators such as Price To Sales Ratio of 22.84, Dividend Yield of 0.0 or Days Sales Outstanding of 72.51. Ascendis financial statements analysis is a perfect complement when working with Ascendis Pharma Valuation or Volatility modules.
Ascendis | Total Assets |
Latest Ascendis Pharma's Total Assets Growth Pattern
Below is the plot of the Total Assets of Ascendis Pharma AS over the last few years. Total assets refers to the total amount of Ascendis Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ascendis Pharma AS books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Ascendis Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ascendis Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 825.59 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Ascendis Total Assets Regression Statistics
| Arithmetic Mean | 409,492,552 | |
| Geometric Mean | 185,725,403 | |
| Coefficient Of Variation | 100.74 | |
| Mean Deviation | 356,963,863 | |
| Median | 210,979,000 | |
| Standard Deviation | 412,517,021 | |
| Sample Variance | 170170.3T | |
| Range | 1.1B | |
| R-Value | 0.83 | |
| Mean Square Error | 55848.7T | |
| R-Squared | 0.70 | |
| Significance | 0.0001 | |
| Slope | 76,912,532 | |
| Total Sum of Squares | 2382384.1T |
Ascendis Total Assets History
Other Fundumenentals of Ascendis Pharma AS
Ascendis Pharma Total Assets component correlations
Click cells to compare fundamentals
About Ascendis Pharma Financial Statements
Ascendis Pharma stakeholders use historical fundamental indicators, such as Ascendis Pharma's Total Assets, to determine how well the company is positioned to perform in the future. Although Ascendis Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascendis Pharma's assets and liabilities are reflected in the revenues and expenses on Ascendis Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascendis Pharma AS. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Assets | 825.6 M | 477.4 M | |
| Intangibles To Total Assets | 0.01 | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| F | Ford Motor | |
| CRM | Salesforce |
Check out the analysis of Ascendis Pharma Correlation against competitors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.